Work

Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.11049

Authors: Kunal C. Potnis, Satoko Ito, Natalia Kunst, Ilana Richman, Eric P. Winer, George Goshua

Institutions: Yale University, University of York, Yale Cancer Center

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410809804

Cites:

Cited by: 4

Related to: 10